Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.51 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137387 | 0.87 | MGLL (0.67) | MGLLMAPT | |
| SCHEMBL20150072 | 0.84 | MGLL (0.52) | MGLLSETD7VEGFAEGLN1TP53 | |
| SCHEMBL20150075 | 0.81 | MGLL (0.47) | MGLLSETD7VEGFAEGLN1KMT2A | |
| SCHEMBL16577092 | 0.80 | ALDH1A1 (0.54) | MGLLSETD7VEGFAEGLN1KMT2A | |
| SCHEMBL19386351 | 0.80 | MGLL (0.48) | MGLLVEGFAEGLN1KMT2AMEN1 | |
| SCHEMBL17109170 | 0.80 | ALDH1A1 (0.58) | MGLLVEGFAEGLN1KMT2AMEN1 | |
| SCHEMBL20150071 | 0.80 | MGLL (0.48) | MGLLVEGFAEGLN1KMT2AMEN1 | |
| SCHEMBL20151870 | 0.80 | MGLL (0.48) | MGLLSETD7VEGFAEGLN1KMT2A | |
| SCHEMBL4502120 | 0.79 | VEGFA (0.49) | MGLLVEGFAEGLN1KMT2AMEN1 | |
| SCHEMBL20151860 | 0.78 | MGLL (0.48) | MGLLSETD7VEGFAEGLN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | MGLL 3/4885SETD7 2756/4885VEGFA 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.